BTCC / BTCC Square / Global Cryptocurrency /
Hims & Hers Health Surges on Potential Wegovy Partnership with Novo Nordisk

Hims & Hers Health Surges on Potential Wegovy Partnership with Novo Nordisk

Published:
2025-11-04 08:32:02
14
2
BTCCSquare news:

Hims & Hers Health (HIMS) shares rallied 5.65% in pre-market trading following news of discussions with Novo Nordisk (NVO) to offer weight-loss drugs Wegovy and oral Wegovy through its platform. The potential partnership signals a strategic MOVE into the booming weight-loss market, overshadowing mixed Q3 results that saw EPS miss estimates ($0.06 vs. $0.10 expected) while revenue beat forecasts ($599M vs. $580M expected).

No definitive agreement has been reached, and terms may differ from current expectations. Novo Nordisk's oral Wegovy WOULD only be available post-FDA approval. The talks highlight Hims & Hers' push to expand its healthcare offerings beyond prescription medications and online consultations.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.